Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) FCF Margin (2016 - 2025)

Editas Medicine (EDIT) has disclosed FCF Margin for 11 consecutive years, with 416.15% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin rose 7721828.0% to 416.15% in Q3 2025 year-over-year; TTM through Sep 2025 was 388.28%, a 9790.0% decrease, with the full-year FY2024 number at 650.95%, down 48068.0% from a year prior.
  • FCF Margin was 416.15% for Q3 2025 at Editas Medicine, up from 1403.35% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 32.76% in Q4 2023 to a low of 122311.9% in Q3 2022.
  • A 5-year average of 12420.34% and a median of 729.97% in 2022 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: plummeted -12166154bps in 2022, then soared 12164290bps in 2023.
  • Editas Medicine's FCF Margin stood at 336.53% in 2021, then crashed by -83bps to 615.35% in 2022, then soared by 95bps to 32.76% in 2023, then crashed by -406bps to 165.64% in 2024, then crashed by -151bps to 416.15% in 2025.
  • Per Business Quant, the three most recent readings for EDIT's FCF Margin are 416.15% (Q3 2025), 1403.35% (Q2 2025), and 1026.17% (Q1 2025).